Press release

Switzerland, 18 September 2023 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the launch of its Series C for the next stage of the company’s development. CUTISS seeks to raise the Series C with the participation of existing and new investors to take its personalized skin …

CUTISS launches Series C financing round to advance the development of its personalized skin technology, paving the way towards commercialization Read More »

CUTISS announces results from Phase 2 clinical trials for denovoSkin™ in adolescent and adult burn patients, and Phase 1 in children Phase 2 clinical trial reaches efficacy endpoint with high statistical significance for lead product denovoSkin™ in adult and adolescent burn patients. Phase 1 clinical trial of denovoSkin™ is completed with 5-year follow up demonstrating …

CUTISS announces positive Phase 2 clinical trial results for denovoSkin™ Read More »

As part of the company’s R&D in regenerative medicine, CUTISS will observe the effects of space on skin cells and tissue culture. Research implications towards human safety in space travel and new discoveries in regenerative medicine and tissue engineering on Earth. Four-week mission conducted in collaboration with SpacePharma which specializes in space-based experiments and micro-lab …

Advanced testing of human skin cells on the International Space Station to push the boundaries of innovation in regenerative medicine Read More »

Switzerland, 7 November 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced that the company is invited to the upcoming Jefferies London Healthcare Conference, taking place November 15 – 17, 2022. Dr Daniela Marino, Chief Executive Officer and co-founder at CUTISS, will attend the conference …

CUTISS to participate in Jefferies London Healthcare Conference 2022 Read More »

PRESS RELEASE CUTISS completes recruitment for denovoSkin™ Phase 2 clinical trial in adult and adolescent burn patients Switzerland, 7 September 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the completion of recruitment for the Phase 2 clinical trial of its lead product denovoSkin™ …

Recruitment completed for denovoSkin Phase 2 clinical trial, adult & adolescent patients Read More »

CUTISS achieves full independence in its manufacturing capabilities with onsite facility. Increased agility and capacity in producing denovoSkin for current and future clinical trials and patients on compassionate basis. Successful transfer of technology and departure from Wyss Zurich Translational Center, a joint accelerator created by Hansjörg Wyss together with the University of Zurich and ETH …

CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator Read More »

PRESS RELEASE  Two innovative biotechnology specialists, IBSA Pharma and CUTISS complete license agreement for VitiCell® Agreement grants CUTISS exclusive worldwide license to commercialize VitiCell®. VitiCell® is a CE marked medical device developed by IBSA for the treatment of skin pigmentation disorders. Strategic fit with CUTISS’s expertise in skin tissue bioengineering. Sophia-Antipolis (France) and Zurich (Switzerland), 2 …

IBSA Pharma and CUTISS complete license agreement for VitiCell Read More »

CUTISS opens subsidiary in France and secures first government grant to extend its Research and Development in regenerative medicine The subsidiary CUTISS Innovation, based at Sophia Antipolis, Europe’s leading technology park, will focus on R&D and innovation in regenerative medicine. A grant of EUR 300,000 from the Region Provence-Alpes-Cote d’Azur will contribute towards the installation …

CUTISS opens R&D subsidiary in France and secures first grant Read More »

CUTISS develops world’s first machine to produce personalized human skin tissue therapy A world-first innovation in tissue engineering and regenerative medicine that can lead to life-saving and life-changing medical treatments for millions of people with severe skin injuries Over 11 million people annually suffer from severe burns needing surgery Significant milestone in the company’s automation …

CUTISS develops world’s first machine to produce personalized human tissue Read More »

CUTISS enhances Management Team by appointing Chief Financial Officer